MX2009008413A - Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. - Google Patents

Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.

Info

Publication number
MX2009008413A
MX2009008413A MX2009008413A MX2009008413A MX2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A MX 2009008413 A MX2009008413 A MX 2009008413A
Authority
MX
Mexico
Prior art keywords
compositions
prevention
treatment
administered
immune response
Prior art date
Application number
MX2009008413A
Other languages
English (en)
Inventor
Tai June Yoo
Original Assignee
Tai June Yoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tai June Yoo filed Critical Tai June Yoo
Publication of MX2009008413A publication Critical patent/MX2009008413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se proporcionan composiciones y métodos para tratar y/o prevenir una enfermedad neurodegenerativa, tal como enfermedad de Alzheimer. En aspectos particulares, las composiciones administradas en este documento codifican un elemento de respuesta inmune celular. Las composiciones pueden prepararse y administrarse de manera tal que la secuencia codificante del elemento de respuesta inmune celular se expresa en el sujeto al que se administra la composición. Las composiciones incluyen sistemas de expresión, sistemas de suministro, y ciertos genes de elementos de respuesta inmune celular.
MX2009008413A 2007-02-06 2008-02-04 Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. MX2009008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90013807P 2007-02-06 2007-02-06
PCT/US2008/052953 WO2008097927A2 (en) 2007-02-06 2008-02-04 Treatment and prevention of neurodegenerative diseases using gene therapy

Publications (1)

Publication Number Publication Date
MX2009008413A true MX2009008413A (es) 2009-11-02

Family

ID=39682371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008413A MX2009008413A (es) 2007-02-06 2008-02-04 Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.

Country Status (13)

Country Link
US (2) US8247385B2 (es)
EP (1) EP2114153B1 (es)
JP (1) JP5829377B2 (es)
KR (2) KR101661356B1 (es)
CN (2) CN101652063A (es)
AU (1) AU2008213999B2 (es)
CA (1) CA2677273A1 (es)
IL (1) IL200151A (es)
MX (1) MX2009008413A (es)
NZ (1) NZ579050A (es)
RU (1) RU2471487C2 (es)
WO (1) WO2008097927A2 (es)
ZA (1) ZA200906165B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014987A1 (en) * 2009-03-26 2012-01-19 Yoh Matsumoto Dna vaccine for alzheimer's disease
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
KR101367568B1 (ko) * 2011-05-31 2014-02-27 임우석 Ａｂｃ 수송체 조절을 통한 퇴행성신경질환에서 이상단백질 조절
CN106714845A (zh) * 2014-08-11 2017-05-24 得克萨斯州大学系统董事会 通过crispr/cas9介导的基因编辑预防肌营养不良
RU2652312C2 (ru) * 2016-01-20 2018-04-25 Селл энд Джин Терапи Лтд Линейка биологически активных генно-терапевтических субстанций на основе гена tgfb1 для коррекции патологических состояний клеток органов и тканей и органов и тканей человека, способ получения и использования
CN105748518B (zh) * 2016-03-21 2019-06-07 大连大学 包含脂肪干细胞提取物的抗衰老组合物
US10829528B2 (en) * 2016-07-20 2020-11-10 Vib Vzw Therapeutic agents for neurological and psychiatric disorders
US12068059B2 (en) 2017-01-25 2024-08-20 Whitehead Institute For Biomedical Research Methods for building genomic networks and uses thereof
EP3754025A4 (en) * 2018-01-24 2022-01-26 Slbigen Inc. MESENCHYMAL STEM CELLS WITH BRAIN-DERIVED NEUROTROPHIC FACTOR EXPRESSION AND THEIR USE
US20210079050A1 (en) * 2018-02-20 2021-03-18 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof
IT201800003279A1 (it) * 2018-03-05 2019-09-05 Consiglio Nazionale Ricerche Peptide neurotrofico per il trattamento terapeutico di patologie neurodegenerative e/o infiammatorie.
CN109942714B (zh) * 2019-04-02 2022-07-08 中国药科大学 一种功能多肽及应用
GB2620875B (en) 2019-04-19 2024-05-08 Synerkine Pharma B V A fusion protein comprising IL13
BR112022007010A2 (pt) * 2019-10-16 2022-07-12 Univ Cornell Terapia gênica para doença de alzheimer
EP3992292A4 (en) * 2020-02-28 2023-06-21 Rznomics Inc. APOE4 RNA SPECIFIC TRANS-SPLICING RIBOZYME AND USE THEREOF

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
EP0391960B1 (en) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
JPH04507041A (ja) 1988-12-13 1992-12-10 アメリカ合衆国 遺伝工学により修飾された内皮細胞およびその利用方法
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
AU665176B2 (en) 1990-09-21 1995-12-21 Novartis Vaccines And Diagnostics, Inc. Packaging cells
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
JP3547129B2 (ja) 1991-02-19 2004-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変更宿主域を有するウィルス粒子
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
EP0695186A1 (en) 1993-04-28 1996-02-07 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
EP0961830A1 (en) * 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US6034072A (en) 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
PT1028737E (pt) 1997-07-03 2007-07-11 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas de sangue periférico
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO2002007774A2 (en) * 2000-07-19 2002-01-31 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
RU2238947C2 (ru) 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
BR9912819A (pt) 1998-07-14 2001-05-02 Janssen Pharmaceutica Nv Fator de crescimento neurotrófico
CA2407074A1 (en) 2000-04-21 2001-11-01 Jukka Hartikka Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
CN100534436C (zh) * 2001-11-21 2009-09-02 利兰·斯坦福青年大学托管委员会 多核苷酸
GB0212648D0 (en) * 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
US20060073119A1 (en) * 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
JP4855268B2 (ja) * 2004-11-30 2012-01-18 アンジェスＭｇ株式会社 アルツハイマー治療剤
EP1841455A1 (en) * 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
JPWO2007139178A1 (ja) * 2006-05-31 2009-10-15 ディナベック株式会社 アルツハイマー病治療薬

Also Published As

Publication number Publication date
RU2009132196A (ru) 2011-03-20
RU2471487C2 (ru) 2013-01-10
EP2114153B1 (en) 2016-11-23
KR20140102327A (ko) 2014-08-21
US8247385B2 (en) 2012-08-21
AU2008213999B2 (en) 2014-04-17
JP2010518105A (ja) 2010-05-27
ZA200906165B (en) 2012-02-29
CN106890342A (zh) 2017-06-27
IL200151A (en) 2015-06-30
EP2114153A4 (en) 2011-05-11
US20080292603A1 (en) 2008-11-27
WO2008097927A3 (en) 2008-12-18
US20130231632A1 (en) 2013-09-05
CN101652063A (zh) 2010-02-17
WO2008097927A2 (en) 2008-08-14
IL200151A0 (en) 2010-04-15
KR101661356B1 (ko) 2016-09-30
JP5829377B2 (ja) 2015-12-09
KR20090118956A (ko) 2009-11-18
AU2008213999A1 (en) 2008-08-14
EP2114153A2 (en) 2009-11-11
CA2677273A1 (en) 2008-08-14
CN106890342B (zh) 2022-09-23
NZ579050A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
MX2009008413A (es) Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2017191274A3 (en) Rna encoding a therapeutic protein
ZA202002094B (en) Trispecific proteins and methods of use
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
MX2019001920A (es) Arn la terapia contra el cancer.
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
TW200744642A (en) Novel peptides for use in the treatment of obesity
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2008087186A3 (en) Peptides for use in the treatment of obesity
WO2009066060A3 (en) 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
MX367131B (es) Sales de xantilio 3,6-disustituidas.
IL191796A0 (en) Combination of zd6474 and pemetrexed
WO2008087188A3 (en) Peptides for use in the treatment of obesity
IN2014DN06920A (es)
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.

Legal Events

Date Code Title Description
FG Grant or registration